{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:18:42Z","timestamp":1782994722387,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The 90th Anniversary of Chulalongkorn University Scholarship, Ratchadapiseksompotch Fund"},{"name":"Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["RA67\/030"],"award-info":[{"award-number":["RA67\/030"]}]},{"name":"Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["RA67\/030"],"award-info":[{"award-number":["RA67\/030"]}]},{"name":"Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["RA67\/030"],"award-info":[{"award-number":["RA67\/030"]}]},{"name":"Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["RA67\/030"],"award-info":[{"award-number":["RA67\/030"]}]},{"name":"Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["RA67\/030"],"award-info":[{"award-number":["RA67\/030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16328-3","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T05:55:38Z","timestamp":1755842138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and effect of topical neostigmine ophthalmic solution in animal models"],"prefix":"10.1038","volume":"15","author":[{"given":"Chuthamas","family":"Ongprakobkul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supharat","family":"Jariyakosol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supanut","family":"Apinyawasisuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasem","family":"Rattanapinyopituk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pajaree","family":"Chariyavilaskul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornvalee","family":"Meesilpavikkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuda","family":"Chongpison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"16328_CR1","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","volume":"122","author":"L Nagia","year":"2015","unstructured":"Nagia, L., Lemos, J., Abusamra, K. & Cornblath, W. T. Eggenberger E.R. Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology 122, 1517\u20131521 (2015).","journal-title":"Ophthalmology"},{"key":"16328_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00415-019-09631-3","volume":"267","author":"MP Giannoccaro","year":"2020","unstructured":"Giannoccaro, M. P. et al. Sensitivity and specificity of single-fibre EMG in the diagnosis of ocular myasthenia varies accordingly to clinical presentation. J. Neurol. 267, 739\u2013745 (2020).","journal-title":"J. Neurol."},{"key":"16328_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ncl.2018.01.010","volume":"36","author":"M Pasnoor","year":"2018","unstructured":"Pasnoor, M., Dimachkie, M. M., Farmakidis, C. & Barohn, R. J. Diagnosis of myasthenia gravis. Neurol. Clin. 36, 261\u2013274 (2018).","journal-title":"Neurol. Clin."},{"key":"16328_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jneuroim.2009.11.004","volume":"218","author":"C Provenzano","year":"2010","unstructured":"Provenzano, C., Marino, M., Scuderi, F., Evoli, A. & Bartoccioni, E. Anti-acetylcholinesterase antibodies associate with ocular myasthenia Gravis. J. Neuroimmunol. 218, 102\u2013106 (2010).","journal-title":"J. Neuroimmunol."},{"key":"16328_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1055\/s-2004-829591","volume":"24","author":"PI Andrews","year":"2004","unstructured":"Andrews, P. I. Autoimmune myasthenia Gravis in childhood. Semin Neurol. 24, 101\u2013110 (2004).","journal-title":"Semin Neurol."},{"key":"16328_CR6","unstructured":"Neely, G. A., Sabir, S. & Kohli, A. Neostigmine StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470596\/ (2023)."},{"key":"16328_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3341\/kjo.2011.25.1.1","volume":"25","author":"HS Roh","year":"2011","unstructured":"Roh, H. S., Lee, S. Y. & Yoon, J. S. Comparison of clinical manifestations between patients with ocular myasthenia gravis and generalized myasthenia gravis. Korean J. Ophthalmol. 25, 1\u20137 (2011).","journal-title":"Korean J. Ophthalmol."},{"key":"16328_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","volume":"16","author":"M Benatar","year":"2006","unstructured":"Benatar, M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul. Disord. 16, 459\u2013467 (2006).","journal-title":"Neuromuscul. Disord"},{"key":"16328_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/eye.1999.78","volume":"13","author":"GW Nietgen","year":"1999","unstructured":"Nietgen, G. W., Schmidt, J., Hesse, L., H\u00f6nemann, C. W. & Durieux, M. E. Muscarinic receptor functioning and distribution in the eye: molecular basis and implications for clinical diagnosis and therapy. Eye (Lond). 13, 285\u2013300 (1999).","journal-title":"Eye (Lond)"},{"key":"16328_CR10","doi-asserted-by":"crossref","unstructured":"Salih, M.A. et al. Ocular neostigmine drops for diagnosing myasthenia gravis. J. Neurol. Neurophysiol. S11, 004 (2012).","DOI":"10.4172\/2155-9562.S11-004"},{"key":"16328_CR11","unstructured":"OECD. Test No. 405: acute eye irritation\/corrosion, OECD guidelines for the testing of chemicals, section 4. OECD iLibrary. https:\/\/www.oecd-ilibrary.org\/docserver\/9789264185333-en.pdf?expires=1675048604&id=id&accname=guest&checksum=BEA0A37912AFCFEF7DDDC5639CF4F39B (2021)."},{"key":"16328_CR12","doi-asserted-by":"publisher","first-page":"108303","DOI":"10.1016\/j.neuropharm.2020.108303","volume":"182","author":"NK Katz","year":"2021","unstructured":"Katz, N. K. & Barohn, R. J. The history of acetylcholinesterase inhibitors in the treatment of myasthenia Gravis. Neuropharmacology 182, 108303 (2021).","journal-title":"Neuropharmacology"},{"key":"16328_CR13","unstructured":"Andrade, O. A. & Zafar, G. A. Physostigmine (eds) (Archived). StatPearls. https:\/\/www-ncbi-nlm-nih-gov.cumL1.md.chula.ac.th\/books\/NBK545261\/ (2023)."},{"key":"16328_CR14","doi-asserted-by":"crossref","unstructured":"Day, A. C., Nolan, W., Malik, A. N., Viswanathan, A. C. & Foster, P.J. Pilocarpine induced acute angle closure. BMJ Case Rep. 2012:bcr0120125694 (2012).","DOI":"10.1136\/bcr.01.2012.5694"},{"key":"16328_CR15","first-page":"575","volume":"16","author":"A Fossati","year":"1990","unstructured":"Fossati, A., Vimercati, M. G., Bandi, G. L. & Formenti, A. Pharmacokinetic study of neostigmine after intranasal and intravenous administration in the Guinea pig. Drugs Exp. Clin. Res. 16, 575\u2013579 (1990).","journal-title":"Drugs Exp. Clin. Res."},{"key":"16328_CR16","first-page":"193","volume":"13","author":"M Broggini","year":"1991","unstructured":"Broggini, M., Benvenuti, C., Botta, V., Fossati, A. & Valenti, M. Bioavailability of intranasal neostigmine: comparison with intravenous route. Methods Find. Exp. Clin. Pharmacol. 13, 193\u2013198 (1991).","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"16328_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0039-6257(94)90194-5","volume":"39","author":"DA Weinberg","year":"1994","unstructured":"Weinberg, D. A., Lesser, R. L. & Vollmer, T. L. Ocular myasthenia: a protean disorder. Surv. Ophthalmol. 39, 169\u2013210 (1994).","journal-title":"Surv. Ophthalmol."},{"key":"16328_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1476-5381.1980.tb07042.x","volume":"69","author":"SA Smith","year":"1980","unstructured":"Smith, S. A. & Smith, S. E. Subsensitivity to cholinoceptor stimulation of the human iris sphincter in situ following acute and chronic administration of cholinomimetic miotic drugs. Br. J. Pharmacol. 69, 513\u2013518 (1980).","journal-title":"Br. J. Pharmacol."},{"key":"16328_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/08164622.2022.2029683","volume":"105","author":"NH Shuey","year":"2022","unstructured":"Shuey, N. H. Ocular myasthenia gravis: a review and practical guide for clinicians. Clin. Exp. Optom. 105, 205\u2013213 (2022).","journal-title":"Clin. Exp. Optom."},{"key":"16328_CR20","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus, N. E. Myasthenia gravis. N. Engl. J. Med. 375, 2570\u20132581 (2016).","journal-title":"N. Engl. J. Med."},{"key":"16328_CR21","first-page":"257","volume":"7","author":"WT Cornblath","year":"2018","unstructured":"Cornblath, W. T. Treatment of ocular myasthenia gravis. Asia Pac. J. Ophthalmol. (Phila). 7, 257\u2013259 (2018).","journal-title":"Asia Pac. J. Ophthalmol. (Phila)"},{"key":"16328_CR22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00415-025-12922-7","volume":"272","author":"SNM Binks","year":"2025","unstructured":"Binks, S. N. M. et al. Myasthenia gravis in 2025: five new things and four hopes for the future. J. Neurol. 272, 226 (2025).","journal-title":"J. Neurol."},{"key":"16328_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/mus.27851","volume":"68","author":"M Agha","year":"2023","unstructured":"Agha, M., Ismail, H., Sawaya, R. & Salameh, J. Efficacy of Apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: A pilot clinical trial. Muscle Nerve. 68, 206\u2013210 (2023).","journal-title":"Muscle Nerve"},{"key":"16328_CR24","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1097\/OPX.0000000000001800","volume":"98","author":"J Cooper","year":"2021","unstructured":"Cooper, J. & Yang, D. Case report: treatment of myasthenic ptosis with topical ocular oxymetazoline. Optom. Vis. Sci. 98, 1317\u20131320 (2021).","journal-title":"Optom. Vis. Sci."},{"key":"16328_CR25","unstructured":"American Academy of Ophthalmology. 2022\u20132023 Basic and Clinical Science Course. 26 (American Academy of Ophthalmology, 2022)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16328-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16328-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16328-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T19:16:07Z","timestamp":1757445367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16328-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16328"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16328-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30847"}}